|
Mar 11
|
Apellis Pharmaceuticals Inc's Chief Scientific Officer Pascal Deschatelets Sells 69,107 Shares
|
|
Mar 11
|
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
|
|
Feb 15
|
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
|
|
Feb 14
|
Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year?
|
|
Feb 13
|
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
|
|
Jan 12
|
Apellis (APLS): Strong Industry, Solid Earnings Estimate Revisions
|
|
Jan 9
|
Apellis (APLS) Up on Strong Q4 Preliminary Syfovre U.S. Revenues
|
|
Jan 9
|
Apellis Pharmaceuticals, Inc. (APLS) Soars 14.7%: Is Further Upside Left in the Stock?
|
|
Jan 2
|
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 28
|
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
|
|
Dec 18
|
Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks
|
|
Dec 5
|
Nike assumed at Buy, 'near-term challenges well understood': 4 big analyst picks
|
|
Dec 4
|
Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry
|
|
Dec 1
|
Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue?
|
|
Nov 30
|
Apellis Pharmaceuticals' (NASDAQ:APLS) growing losses don't faze investors as the stock rises 5.6% this past week
|
|
Sep 12
|
Insider Sell: Pascal Deschatelets Sells 12,000 Shares of Apellis Pharmaceuticals Inc
|
|
Sep 7
|
Bluebird (BLUE) Up 7.3% Since Last Earnings Report: Can It Continue?
|
|
Sep 6
|
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 6
|
Investing in Apellis Pharmaceuticals (APLS): Navigating the Thin Line Between Value and Trap
|
|
Sep 6
|
Apellis' Waltham office to lose 175 in layoffs
|